Taconic Biosciences Enters Into an Exclusive License Agreement With Helmholtz Munich to Expand Its CRISPR/Cas9 Gene Editing Services
By exclusively licensing Helmholtz Munich's groundbreaking gene editing techniques and applications, Taconic Biosciences strengthens its position as a leader in the commercialization of cutting-edge CRISPR gene editing services.
Share
Through this agreement, Taconic has acquired the exclusive rights to a patented CRISPR-based gene editing technology developed at Helmholtz Munich to improve the generation of genetically modified animal models for biomedical research.
"Taconic is excited to expand our already extensive capabilities in CRISPR/Cas9 gene editing through this new partnership with Helmholtz Munich,' said Mike Garrett, Chief Executive Officer of Taconic Biosciences. 'This technology significantly enhances Taconic's ExpressMODEL ® platform to deliver high-quality, precise CRISPR/Cas9-generated custom animal models on an accelerated timeline to our customers."
Taconic has been a pioneer in CRISPR/Cas9 gene editing services for over a decade and remains at the forefront of advanced gene-modification methodologies. By exclusively licensing Helmholtz Munich's groundbreaking gene editing techniques and applications, Taconic Biosciences strengthens its position as a leader in the commercialization of cutting-edge CRISPR gene editing services.
"This agreement with Taconic will deepen our understanding of gene function by enabling the development of advanced, genetically engineered animal models," said Prof. Dr. Wolfgang Wurst, co-inventor of the licensed technology at Helmholtz Munich. "By combining our innovative CRISPR technology with Taconic's expertise in animal model generation and breeding, we aim to accelerate the creation of precise models that uncover the genetic basis of diseases — supporting scientific discovery and paving the way for future medical breakthroughs.'
This partnership marks a significant milestone in Taconic's commitment to providing researchers with advanced tools for biomedical research. By integrating novel CRISPR/Cas9 technologies with proven expertise in model generation, the collaboration supports the rapid development of scientific breakthroughs and improved translation of genetic research into therapeutic innovation.
To learn more about the ExpressMODEL ® CRISPR Platform and our Custom Model Generation Solutions, visit https://www.taconic.com/custom-model-generation. Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions enabling customers to acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
25 minutes ago
- San Francisco Chronicle
Greenbrier: Fiscal Q3 Earnings Snapshot
LAKE OSWEGO, Ore. (AP) — LAKE OSWEGO, Ore. (AP) — Greenbrier Companies Inc. (GBX) on Tuesday reported earnings of $60.1 million in its fiscal third quarter. The Lake Oswego, Oregon-based company said it had profit of $1.86 per share. The maker of railroad freight car equipment posted revenue of $842.7 million in the period. Greenbrier expects full-year revenue in the range of $3.15 billion to $3.35 billion. _____
Axios
30 minutes ago
- Axios
Spain's Renfe departs from Texas rail project
A Spanish railway company has pulled out of the bullet train project that aims to connect Dallas and Houston. Why it matters: The departure is another setback for the project, which hasn't started construction amid eminent domain challenges, investor changes and federal funding cuts. Flashback: Texas Central Railway in 2018 named Renfe, with routes covering about 9,300 miles in Spain, as an early operator for Texas' future bullet train. Central Japan Railway was chosen to provide the technology. The latest: In April, the U.S. Department of Transportation ended a $64 million grant to Amtrak for the rail project, saying the project is "a waste of taxpayer funds." A Fort Worth-based company joined the project as a lead private investor. But Renfe has liquidated its American subsidiary that was part of the Texas train project, writing off 4.5 million euros in losses, per the Spanish newspaper El Economista. The intrigue: The 240-mile route would get travelers from Dallas to Houston within 90 minutes, per Texas Central. The project is estimated to generate billions of dollars in revenue. Between the lines: Renfe's closure of its American subsidiary indicates the company isn't expecting any returns from the project, El Economista reports.
Business Wire
36 minutes ago
- Business Wire
From Waste to Watts: Argonne is Unlocking the Power in Used Nuclear Fuel
LEMONT, Ill.--(BUSINESS WIRE)--Nuclear reactors across the U.S. generate used fuel, but more than 95% of that fuel still holds valuable energy. Through advanced chemical processes and new technologies, scientists aim to recycle this material to generate more power and reduce long-term radioactive waste. Researchers are now working to make this potential a practical, scalable solution. Scientists at the U.S. Department of Energy's Argonne National Laboratory are partnering with SHINE Technologies, a Wisconsin-based company, to design a new process for separating valuable materials from used nuclear fuel. The process employs innovative equipment, including centrifugal contactors—spinning devices that efficiently separate mixed liquids—to create a safer, more efficient recycling method ready for industrial use. 'Bridging scientific research and industrial implementation is critical,' said Candido Pereira, deputy division director of Argonne's Chemical and Fuel Cycle Technologies (CFCT) division. 'Our team is committed to supporting the private sector with world-class solutions.' Recycling used nuclear fuel is complex. It's highly radioactive, generates heat, and must be safely stored and cooled. Facilities need systems to manage small amounts of leftover material. Nuclear material also requires strict safeguards to prevent unauthorized use. Scientists apply 'safeguards by design' early in development to ensure compliance and security. Economic viability is another hurdle. Recovered materials need practical applications and buyers. Some utilities may use recycled fuel in advanced reactors. Other byproducts—such as radioisotopes—can power space missions or be used in medical diagnostics. If demand exists, building recycling facilities becomes more feasible. Foresight is essential. Scientists must anticipate how future reactors will use fuel and what materials they'll require. Experts at national labs like Argonne are uniquely positioned to predict these needs and tailor recycling processes. Peter Tkac, nuclear chemist and manager of Argonne's CFCT Radiochemistry Group, leads the effort. 'It's important we develop a process that doesn't produce a pure plutonium stream,' he said, citing security risks. Tkac's team uses a Van de Graaff accelerator to simulate radiation conditions and test chemical durability in safe lab environments, speeding innovation. Tkac's group also collaborates with SHINE to test Argonne's centrifugal contactors. Using 3D printing, they build custom prototypes of different designs, allowing rapid, cost-effective testing. 'Recycling used nuclear fuel is complicated,' said Tkac. 'But with the right strategy, we can reduce waste, improve energy supply, and support the future of nuclear power.'
